Display options
Cite
Phensy A, Duzdabanian HE, Brewer S, et al. Antioxidant Treatment with N-acetyl Cysteine Prevents the Development of Cognitive and Social Behavioral Deficits that Result from Perinatal Ketamine Treatment. Front Behav Neurosci. 2017;11:106doi: 10.3389/fnbeh.2017.00106.
Phensy, A., Duzdabanian, H. E., Brewer, S., Panjabi, A., Driskill, C., Berz, A., Peng, G., & Kroener, S. (2017). Antioxidant Treatment with N-acetyl Cysteine Prevents the Development of Cognitive and Social Behavioral Deficits that Result from Perinatal Ketamine Treatment. Frontiers in behavioral neuroscience, 11106. https://doi.org/10.3389/fnbeh.2017.00106
Phensy, Aarron, et al. "Antioxidant Treatment with N-acetyl Cysteine Prevents the Development of Cognitive and Social Behavioral Deficits that Result from Perinatal Ketamine Treatment." Frontiers in behavioral neuroscience vol. 11 (2017): 106. doi: https://doi.org/10.3389/fnbeh.2017.00106
Phensy A, Duzdabanian HE, Brewer S, Panjabi A, Driskill C, Berz A, Peng G, Kroener S. Antioxidant Treatment with N-acetyl Cysteine Prevents the Development of Cognitive and Social Behavioral Deficits that Result from Perinatal Ketamine Treatment. Front Behav Neurosci. 2017 Jun 06;11:106. doi: 10.3389/fnbeh.2017.00106. eCollection 2017. PMID: 28634445; PMCID: PMC5459895.
Copy Download .nbib Format: NLM
Share it on

Front Behav Neurosci. 2017 Jun 06;11:106. doi: 10.3389/fnbeh.2017.00106. eCollection 2017.

Antioxidant Treatment with N-acetyl Cysteine Prevents the Development of Cognitive and Social Behavioral Deficits that Result from Perinatal Ketamine Treatment.

Frontiers in behavioral neuroscience

Aarron Phensy, Hasmik E Duzdabanian, Samantha Brewer, Anurag Panjabi, Christopher Driskill, Annuska Berz, George Peng, Sven Kroener

Affiliations

  1. School of Behavioral and Brain Sciences, The University of Texas at DallasRichardson, TX, United States.

PMID: 28634445 PMCID: PMC5459895 DOI: 10.3389/fnbeh.2017.00106

Abstract

Alterations of the normal redox state can be found in all stages of schizophrenia, suggesting a key role for oxidative stress in the etiology and maintenance of the disease. Pharmacological blockade of N-methyl-D-aspartic acid (NMDA) receptors can disrupt natural antioxidant defense systems and induce schizophrenia-like behaviors in animals and healthy human subjects. Perinatal administration of the NMDA receptor (NMDAR) antagonist ketamine produces persistent behavioral deficits in adult mice which mimic a range of positive, negative, and cognitive symptoms that characterize schizophrenia. Here we tested whether antioxidant treatment with the glutathione (GSH) precursor N-acetyl-cysteine (NAC) can prevent the development of these behavioral deficits. On postnatal days (PND) 7, 9 and 11, we treated mice with subanesthetic doses (30 mg/kg) of ketamine or saline. Two groups (either ketamine or saline treated) also received NAC throughout development. In adult animals (PND 70-120) we then assessed behavioral alterations in a battery of cognitive and psychomotor tasks. Ketamine-treated animals showed deficits in a task of cognitive flexibility, abnormal patterns of spontaneous alternation, deficits in novel-object recognition, as well as social interaction. Developmental ketamine treatment also induced behavioral stereotypy in response to an acute amphetamine challenge, and it impaired sensorimotor gating, measured as reduced prepulse inhibition (PPI) of the startle response. All of these behavioral abnormalities were either prevented or strongly ameliorated by NAC co-treatment. These results suggest that oxidative stress is a major factor for the development of the ketamine-induced behavioral dysfunctions, and that restoring oxidative balance during the prodromal stage of schizophrenia might be able to ameliorate the development of several major symptoms of the disease.

Keywords: amphetamine-induced hyperlocomotion; cognitive flexibility; ketamine; novel object recognition; oxidative stress; prepulse inhibition; social interaction; spontaneous alternation

References

  1. Am J Hum Genet. 2006 Sep;79(3):586-92 - PubMed
  2. Schizophr Res. 2004 Dec 15;72(1):29-39 - PubMed
  3. Neurosci Biobehav Rev. 2002 Jan;26(1):91-104 - PubMed
  4. Synapse. 2000 Dec 15;38(4):369-74 - PubMed
  5. Neurochem Res. 2008 Mar;33(3):508-17 - PubMed
  6. PLoS One. 2013 Jun 11;8(6):e66695 - PubMed
  7. Curr Opin Neurobiol. 2009 Apr;19(2):220-30 - PubMed
  8. Handb Exp Pharmacol. 2012;(213):39-79 - PubMed
  9. Schizophr Res. 1996 Mar;19(1):1-17 - PubMed
  10. J Neurosci. 2010 Aug 25;30(34):11317-25 - PubMed
  11. Schizophr Bull. 2015 Jul;41(4):835-46 - PubMed
  12. Psychopharmacology (Berl). 1998 Jan;135(2):182-93 - PubMed
  13. Eur J Pharmacol. 2010 Dec 15;649(1-3):224-8 - PubMed
  14. Biol Psychiatry. 2013 Sep 15;74(6):400-9 - PubMed
  15. Pharmacol Biochem Behav. 1986 Jul;25(1):233-48 - PubMed
  16. Neurosci Biobehav Rev. 2015 Jan;48:10-21 - PubMed
  17. Behav Brain Res. 2009 Dec 7;204(2):396-409 - PubMed
  18. Schizophr Res. 2012 Aug;139(1-3):66-72 - PubMed
  19. Brain Res Rev. 2007 Feb;53(2):260-70 - PubMed
  20. Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2569-74 - PubMed
  21. Am J Psychiatry. 1994 Mar;151(3):363-7 - PubMed
  22. Neuropsychopharmacology. 1997 Sep;17(3):141-50 - PubMed
  23. Psychopharmacology (Berl). 2007 Sep;193(4):521-37 - PubMed
  24. Compr Psychiatry. 2006 Mar-Apr;47(2):136-43 - PubMed
  25. Science. 2007 Dec 7;318(5856):1645-7 - PubMed
  26. Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16621-6 - PubMed
  27. Curr Pharm Des. 2010;16(5):488-501 - PubMed
  28. Neurosci Biobehav Rev. 2016 Sep;68:979-1000 - PubMed
  29. Eur J Neurosci. 2000 Oct;12(10):3721-8 - PubMed
  30. J Neuropsychiatry Clin Neurosci. 1996 Winter;8(1):60-6 - PubMed
  31. J Neurosci. 2010 Feb 17;30(7):2547-58 - PubMed
  32. Curr Neuropharmacol. 2011 Mar;9(1):251-5 - PubMed
  33. PLoS One. 2014 Oct 07;9(10):e109303 - PubMed
  34. Behav Neurosci. 2003 Aug;117(4):728-37 - PubMed
  35. Arch Gen Psychiatry. 1990 Feb;47(2):181-8 - PubMed
  36. Am J Psychiatry. 1996 Mar;153(3):321-30 - PubMed
  37. Curr Top Behav Neurosci. 2012;12:251-318 - PubMed
  38. Psychopharmacology (Berl). 2009 Jan;202(1-3):315-28 - PubMed
  39. J Am Acad Child Adolesc Psychiatry. 2003 Jun;42(6):666-72 - PubMed
  40. Eur J Pharmacol. 1974 Sep;28(1):35-41 - PubMed
  41. Curr Top Behav Neurosci. 2016;29:403-28 - PubMed
  42. Neuroreport. 2001 Sep 17;12(13):2971-4 - PubMed
  43. Neurobiol Learn Mem. 2011 Nov;96(4):544-52 - PubMed
  44. Biol Psychiatry. 2005 Feb 15;57(4):433-6 - PubMed
  45. Behav Brain Res. 2011 Jan 1;216(1):247-54 - PubMed
  46. Mol Psychiatry. 1999 Mar;4(2):163-72 - PubMed
  47. Neuropsychopharmacology. 2006 Feb;31(2):297-309 - PubMed
  48. Antioxid Redox Signal. 2008 Aug;10(8):1435-47 - PubMed
  49. Neuron. 2014 Sep 3;83(5):1073-84 - PubMed
  50. Mol Psychiatry. 2004 Jul;9(7):684-97, 643 - PubMed
  51. ACS Chem Neurosci. 2015 Jul 15;6(7):987-1016 - PubMed
  52. Arch Gen Psychiatry. 2008 Jan;65(1):28-37 - PubMed
  53. Biol Psychiatry. 2009 Aug 15;66(4):384-92 - PubMed
  54. Antioxid Redox Signal. 2011 May 15;14(10):2013-54 - PubMed
  55. Psychopharmacology (Berl). 2015 Nov;232(21-22):4085-97 - PubMed
  56. Exp Brain Res. 2009 Aug;197(3):215-22 - PubMed
  57. J Pharmacol Exp Ther. 2003 Jan;304(1):266-71 - PubMed
  58. Psychopharmacology (Berl). 2013 Apr;226(3):531-40 - PubMed
  59. Pharmacol Ther. 2010 Dec;128(3):419-32 - PubMed
  60. Biol Psychiatry. 2000 Oct 1;48(7):651-7 - PubMed
  61. Essays Neurochem Neuropharmacol. 1981;5:95-129 - PubMed
  62. Brain Cogn. 2008 Aug;67(3):247-53 - PubMed
  63. Pharmacol Ther. 2009 May;122(2):150-202 - PubMed
  64. Schizophr Bull. 2000;26(1):217-32 - PubMed
  65. Acta Psychiatr Scand. 1999 Aug;100(2):105-18 - PubMed
  66. Behav Brain Res. 2015 Oct 1;292:241-51 - PubMed
  67. Learn Mem. 2002 Jan-Feb;9(1):18-28 - PubMed
  68. Arch Gen Psychiatry. 1999 Mar;56(3):277-81 - PubMed
  69. JAMA Psychiatry. 2013 Oct;70(10):1107-12 - PubMed
  70. Int J Neuropsychopharmacol. 2011 Feb;14(1):123-30 - PubMed
  71. Antioxid Redox Signal. 2014 Jan 10;20(2):247-66 - PubMed
  72. Neuropharmacology. 2012 Mar;62(3):1322-31 - PubMed
  73. Br J Psychiatry. 2005 Jan;186:18-25 - PubMed
  74. Antioxid Redox Signal. 2011 Oct 1;15(7):2057-65 - PubMed
  75. Cereb Cortex. 2016 Mar;26(3):1117-29 - PubMed
  76. Neuroscience. 2008 Jun 23;154(2):454-60 - PubMed
  77. Curr Pharm Des. 2014;20(31):5104-14 - PubMed
  78. Behav Brain Res. 2007 Nov 22;184(1):31-8 - PubMed
  79. Behav Brain Res. 2015 Apr 1;282:165-75 - PubMed
  80. Schizophr Res. 1997 Feb 28;23(3):197-204 - PubMed
  81. Brain Res Bull. 2010 Sep 30;83(3-4):147-61 - PubMed
  82. Am J Psychiatry. 1991 Oct;148(10):1301-8 - PubMed
  83. Schizophr Res. 2004 Dec 15;72(1):41-51 - PubMed
  84. Arch Gen Psychiatry. 2002 Jul;59(7):663-4 - PubMed
  85. Eur Neuropsychopharmacol. 2010 Jan;20(1):37-48 - PubMed
  86. Proc Natl Acad Sci U S A. 1996 Aug 20;93(17 ):9235-40 - PubMed
  87. J Neurosci. 2007 Mar 14;27(11):2948-57 - PubMed
  88. Schizophr Bull. 2009 May;35(3):549-62 - PubMed
  89. Brain Res. 1986 Jun;396(2):157-98 - PubMed
  90. J Psychiatr Res. 2001 Mar-Apr;35(2):119-25 - PubMed
  91. J Neurosci. 2000 Jun 1;20(11):4320-4 - PubMed
  92. Brain. 2016 Dec;139(Pt 12):3281-3295 - PubMed
  93. Psychopharmacology (Berl). 1995 Nov;122(1):35-43 - PubMed
  94. Pharmacol Biochem Behav. 2009 Sep;93(3):322-30 - PubMed
  95. Neurosci Biobehav Rev. 2011 Jan;35(3):878-93 - PubMed
  96. Pharmacol Biochem Behav. 2007 Jan;86(1):1-7 - PubMed
  97. Psychopharmacology (Berl). 2007 Jul;192(4):511-9 - PubMed
  98. Behav Brain Res. 2005 Jan 6;156(1):139-43 - PubMed
  99. Clin Neuropharmacol. 2013 Nov-Dec;36(6):185-92 - PubMed
  100. Neuropharmacology. 2007 Mar;52(4):1179-87 - PubMed
  101. Cogn Affect Behav Neurosci. 2010 May;10(2):243-51 - PubMed
  102. Neuropsychopharmacology. 2007 Mar;32(3):514-21 - PubMed
  103. Dialogues Clin Neurosci. 2006;8(1):109-13 - PubMed
  104. Schizophr Res. 2008 Feb;99(1-3):119-24 - PubMed
  105. Scand J Psychol. 2001 Jul;42(3):239-50 - PubMed
  106. Behav Brain Res. 2008 Jun 26;190(1):160-3 - PubMed
  107. Psychopharmacology (Berl). 2001 Jul;156(2-3):194-215 - PubMed
  108. Biol Psychiatry. 2008 Sep 1;64(5):361-8 - PubMed
  109. Neurobiol Dis. 2002 Apr;9(3):282-93 - PubMed
  110. Trends Neurosci. 2012 Jan;35(1):57-67 - PubMed
  111. Neuropsychopharmacology. 2008 Aug;33(9):2187-99 - PubMed
  112. Schizophr Res. 1999 Jun 22;37(3):251-70 - PubMed
  113. Neuropsychopharmacology. 1995 Aug;13(1):9-19 - PubMed
  114. Biol Psychiatry. 2013 Mar 15;73(6):574-82 - PubMed
  115. Schizophr Bull. 2010 Mar;36(2):246-70 - PubMed
  116. Dis Markers. 2006;22(1-2):83-93 - PubMed
  117. Curr Top Behav Neurosci. 2010;4:435-81 - PubMed
  118. Neurosci Biobehav Rev. 2016 Aug;67:41-56 - PubMed
  119. Psychol Med. 2017 Apr;47(5):866-876 - PubMed
  120. Nat Rev Neurosci. 2016 Feb;17 (2):125-34 - PubMed
  121. Schizophr Res. 2013 Feb;143(2-3):301-6 - PubMed
  122. Am J Psychiatry. 1998 Jun;155(6):761-7 - PubMed
  123. Pharmacol Rep. 2008 Nov-Dec;60(6):856-64 - PubMed
  124. Genes Brain Behav. 2004 Oct;3(5):287-302 - PubMed
  125. Trends Pharmacol Sci. 2013 Mar;34(3):167-77 - PubMed
  126. Psychopharmacology (Berl). 2005 Aug;181(1):134-44 - PubMed

Publication Types